Neha Krishnamohan, CFO and Chief Business Officer of Latigo Biotherapeutics, Inc. (NASDAQ:LTGO), filed a Form 4 on November 18, 2026, disclosing the acquisition of 175,000 employee stock options on November 15, 2026.
Key Highlights
- Grant date: The option award was dated November 15, 2026, with an exercise price of $13.11 per share.
- Option quantity: 175,000 employee stock options (right to buy) in Common Stock were acquired, with transaction code A.
- Price of derivative security: The filing reports the price of the derivative security as $0.
- Vesting schedule: 25% of shares vest on March 31, 2027; 25% vest on November 3, 2027; and 50% vest on May 3, 2028.
- Expiration date: The options expire on November 14, 2036.
- Beneficial ownership following transaction: Krishnamohan Neha holds 175,000 derivative securities directly following this reported transaction.
Latigo Biotherapeutics CFO Option Grant Details and Vesting Terms
According to the Form 4 filed with the SEC on November 18, 2026, Neha Krishnamohan, identified in the filing as CFO and Chief Business Officer of Latigo Biotherapeutics, Inc., received a grant of 175,000 employee stock options on November 15, 2026. The options carry an exercise price of $13.11 and are reported as a direct holding. The filing records the price of the derivative security as $0 and notes the transaction code as A, indicating acquisition.
The filing discloses a three-tranche vesting schedule. Per the explanation of responses, "25% of the total shares subject to this option shall vest on March 31, 2027, 25% of the total shares subject to this option shall vest on November 3, 2027, and 50% of the total shares subject to this option shall vest on May 3, 2028." The options are exercisable into Common Stock, with an expiration date of November 14, 2036. Following this transaction, the filing reports that Krishnamohan Neha beneficially owns 175,000 derivative securities on a direct basis.
No transactions were reported in Table I covering non-derivative securities. The Form 4 was signed by Sabrina Nieder as Attorney-in-Fact on November 18, 2026, and was filed as an individual, single-reporting-person submission. No amendment date was provided, indicating this is an original filing.
What Was Disclosed
Latigo Biotherapeutics CFO and Chief Business Officer Neha Krishnamohan disclosed the acquisition of 175,000 employee stock options at an exercise price of $13.11, granted November 15, 2026, expiring November 14, 2036, with a staged vesting schedule ending May 3, 2028.





Please wait processing your request...